Project Grant R21DE032844
- This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
- Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $442,750 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) for the period July 1, 2025 through June 30, 2027. The award funds research to systematically identify drivers controlling interactions between Fusobacterium nucleatum (FN), a bacterium commonly found in oral...
- Summary of Federal Project Grant Award Oregon Health & Science University received a $234,000 project grant awarded on June 10, 2025, from the National Institute of Dental and Craniofacial Research under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant funds research to develop genetic manipulation tools and systems for Prevotella melaninogenica, an abundant oral bacterium implicated in polymicrobial abscesses and various malignancies. The project addresses a...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $1.39 million Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), effective July 1, 2025, through March 31, 2030. The award funds development of an organ-on-a-chip model to investigate oral squamous cell carcinoma (OSCC) invasion into bone tissue. This in vitro research platform replicates the complex...
- This $294,244 Project Grant award, funded by the Department of Health and Human Services (DHHS) Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program, supports research to identify sepsis phenotypes associated with antibiotic-resistant pathogens. The project aims to leverage machine learning techniques, including large language models applied to clinical notes, to augment electronic health record (EHR) data and define...
- This $515,926 Project Grant awarded by the National Science Foundation (NSF) Engineering program (CFDA 47.041) will fund research to develop an in vitro gingival (gum) tissue system to study the role of microbial communities on oral health and disease. The 5-year project, beginning June 1, 2024, will be conducted by the University of Massachusetts Lowell's Office of Research Administration-Lowell. The key objectives are: (1) developing and validating a microphysiological system to study oral...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded $426,250 to the University of Kansas Medical Center Research Institute, Inc. on August 14, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to support basic research on pathogenic mechanisms in Streptococcus sanguinis. The two-year project, concluding August 13, 2027, will characterize two endopeptidases (SEPM homologs) encoded by this oral bacterium that can...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded $540,629 to the University of Massachusetts Lowell on August 15, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to support research investigating human oral host-pathogen interactions and dysbiosis modulation. The project, scheduled for completion by August 14, 2027, focuses on developing and validating an immunocompetent three-dimensional (3D) in vitro model...
- This $314,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to gain insights into the evolution of fungal resistance in the oral environment of HIV-positive individuals. The research will leverage an existing patient dataset to: 1) use long-read sequencing to profile the fungal mycobiome in patient saliva and caries samples, and 2) perform longitudinal...
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded Cedars-Sinai Medical Center a $1,240,877 Project Grant on August 15, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop bioengineered vascularized oral tissue grafts derived from induced pluripotent stem cells (iPSCs). This team science initiative, with completion targeted for May 31, 2030, pursues three primary objectives: (1) identifying molecular pathways...
DEFINING THE MECHANISMS OF SURGICAL SITE INFECTION AFTER ORAL CANCER SURGERY USING PERI-OPERATIVE METAGENOMICS - PROJECT SUMMARY ORAL CAVITY RECONSTRUCTION (OCR), WHICH INVOLVES OPEN SURGICAL RESECTION OF ORAL CANCER WITH VASCULARIZED TISSUE FLAP RECONSTRUCTION, REMAINS A CENTRAL COMPONENT OF ONCOLOGIC MANAGEMENT. HOWEVER, A MAIN SOURCE OF PERI- OPERATIVE MORBIDITY AFTER SUCH SURGERIES IS SURGICAL SITE INFECTION (SSI), WHICH CONTINUES TO OCCUR IN AT LEAST 20% OF CASES NATIONWIDE. POST-OPERATIVE SSI LEADS TO SIGNIFICANT PHYSICAL, PSYCHOSOCIAL, AND FINANCIAL BURDENS ON PATIENTS AND MAY COMPROMISE CANCER CONTROL BY DELAYING NECESSARY POST-OPERATIVE RADIATION. IN OCR, THERE ARE MULTIPLE OPPORTUNITIES FOR BACTERIAL CONTAMINATION OF THE SURGICAL FIELD LEADING TO SSI. WHILE COMMON ORAL MICROBIOTA CAN CAUSE SSI, MOST INFECTIONS ARE DUE TO PATHOGENS NOT TYPICALLY FOUND AMONG THE HEALTHY ORAL MICROBIOME, SUCH AS STAPHYLOCOCCUS AND PSEUDOMONAS SPP. THE SOURCE OF THESE BACTERIA AND THEIR MECHANISM OF INFECTION HAVE NOT BEEN ESTABLISHED. TO REDUCE SSI AFTER OCR, AND THEREBY PREVENT PATIENT SUFFERING, LIMIT HEALTHCARE COSTS, AND AVOID DELAYS IN NECESSARY POST-OPERATIVE RADIATION, WE MUST ADDRESS THESE SIGNIFICANT GAPS IN CURRENT KNOWLEDGE. OUR PRELIMINARY STUDIES SUGGEST THAT THE ORAL ENVIRONMENT IS THE LIKELY SOURCE OF SUCH INFECTIONS AND THAT GENOMIC TECHNIQUES CAN BE USED TO TRACK BACTERIAL STRAINS ACROSS THE TREATMENT PERIOD. BUILDING ON OUR PRELIMINARY DATA, WE PROPOSE A STUDY WITH THE FOLLOWING SPECIFIC AIMS: AIM 1) IDENTIFY THE PERI-OPERATIVE SOURCE OF BACTERIA WHICH LEAD TO SSI AFTER OCR IN ORAL CANCER PATIENTS; AND AIM 2) DETERMINE THE MECHANISMS OF BACTERIAL ANTIBIOTIC RESISTANCE IN ORAL CANCER PATIENTS WHO DEVELOP SSI AFTER OCR. PATIENTS PLANNED FOR STANDARD OF CARE OCR WILL BE RECRUITED TO UNDERGO PERI-OPERATIVE BACTERIAL SAMPLING, INCLUDING SKIN, ORONASAL, AND PHARYNGOESOPHAGEAL SITES. FOR PATIENTS WHO EXPERIENCE SSI, THE PURULENCE FROM THE INFECTION WILL ALSO BE SAMPLED. IN AIM 1, WE WILL DETERMINE WHICH PERI-OPERATIVE SITES MAY BE THE SOURCE OF INFECTION. WE WILL ACCOMPLISH THIS FIRST BY TESTING PERI-OPERATIVE SAMPLES FOR THE PRESENCE OF BACTERIA KNOWN TO CAUSE SSI AFTER OCR. THEN, WE WILL MORE PRECISELY IDENTIFY THE SITE AND MECHANISM BY MATCHING THE GENOME SEQUENCE OF THE INFECTIOUS BACTERIA TO IDENTICAL STRAINS AMONG THE PERI-OPERATIVE MICROBIOTA. IN AIM 2, WE WILL INVESTIGATE THE MECHANISMS OF ANTIBIOTIC RESISTANCE. WE WILL DETERMINE IF INSUFFICIENT ANTIBIOTIC PENETRATION IS AN ETIOLOGY OF INFECTION BY QUANTIFYING AMPICILLIN/SULBACTAM CONCENTRATIONS IN BOTH TISSUE AND BLOOD DURING SURGERY. NEXT, WE WILL EXAMINE GENETIC RESISTANCE MECHANISMS BY IDENTIFYING AND TRACKING ANTIBIOTIC RESISTANCE GENES HARBORED BY INFECTIOUS ORGANISMS ACROSS THE TREATMENT PERIOD. THESE DATA WILL ILLUMINATE THE POTENTIAL SOURCE OF BACTERIA THAT LEAD TO SSI AFTER OCR AND WILL FURTHER DEVELOP THE MECHANISMS LEADING TO INFECTION. THIS WILL PROVIDE A STRONG FOUNDATION TO DESIGN PRECISION THERAPEUTICS IN FUTURE STUDIES TO BETTER PREVENT SSI AFTER OCR. THESE INTERVENTIONS MAY INCLUDE TARGETED ANTISEPTICS AND IMPROVED METHODS OF ANTIBIOTIC DELIVERY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/2/26 | ||
| Not listed | $19.5k | 5/9/25 | ||
| Not listed | $19.5k | 5/9/25 | ||
| Not listed | $0 | 4/30/25 | ||
| Not listed | $0 | 4/30/25 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
R21DE0328441S | University Of Houston System | Project Grant R21DE032844 | $43.4k | 8/27/25 |